Table 1.
Characteristics of AAV patients with MetS.
| Variables | Values |
|---|---|
| At the time of diagnosis | |
| Demographic data | |
| Age (years) | 51.2 (11.2) |
| Sex (n, (%)) | |
| Male | 13 (36.1) |
| Female | 23 (63.9) |
| Body mass index (kg/m2) | 23.1 (2.9) |
| AAV Subtypes (n, (%)) | |
| MPA | 18 (50.0) |
| GPA | 8 (22.2) |
| EGPA | 10 (27.8) |
| ANCA type (n, (%)) | |
| MPO-ANCA (or P-ANCA) positive | 25 (69.4) |
| PR3-ANCA (or C-ANCA) positive | 5 (13.9) |
| Both ANCA positive | 0 (0) |
| ANCA positive | 30 (83.3) |
| AAV-specific indices | |
| BVAS | 12.5 (13.0) |
| FFS | 1.0 (2.0) |
| Laboratory results | |
| White blood cell count (/mm3) | 1820.0 (6170.0) |
| Haemoglobin (g/dL) | 11.1 (3.5) |
| Platelet count (×1000/mm3) | 320.0 (113.0) |
| Blood urea nitrogen (mg/dL) | 21.7 (32.6) |
| Serum creatinine (mg/dL) | 1.1 (2.8) |
| eGFR | 60.8 (76.1) |
| Serum albumin (g/dL) | 3.6 (0.8) |
| Acute-phase reactants | |
| ESR (mm/hr) | 62.0 (51.0) |
| CRP (mg/L) | 8.5 (82.4) |
| MSSS variables | |
| Waist circumference (cm) | 84.3 (9.1) |
| Systolic blood pressure (mmHg) | 130.0 (10.0) |
| Triglyceride (mg/dL) | 146.0 (81.0) |
| HDL-cholesterol (mg/dL) | 43.0 (17.0) |
| Fasting plasma glucose (mg/dL) | 100.5 (38.5) |
| MSSS | 1.1 (1.0) |
| During follow-up | |
| Poor outcomes and follow-up duration | |
| All-cause mortality (n, (%)) | 1 (2.8) |
| Follow-up duration based on all-cause mortality (months) | 61.0 (100.8) |
| Relapse (n, (%)) | 20 (55.6) |
| Follow-up duration based on relapse (months) | 15.9 (49.1) |
| ESKD (n, (%)) | 10 (27.8) |
| Follow-up duration based on ESKD (months) | 20.4 (107.6) |
| CVA (n, (%)) | 2 (5.6) |
| Follow-up duration based on CVA (months) | 58.2 (101.3) |
| CVD (n, (%)) | 5 (13.9) |
| Follow-up duration based on CVD (months) | 55.5 (95.8) |
| Medications administered during follow-up (n, (%)) | |
| Glucocorticoid | 36 (100) |
| Cyclophosphamide | 20 (55.6) |
| Rituximab | 8 (22.2) |
| Mycophenolate mofetil | 7 (19.4) |
| Azathioprine | 17 (47.2) |
| Tacrolimus | 1 (2.8) |
| Methotrexate | 2 (5.6) |
Values are expressed as a median (interquartile range, IQR) or n (%). AAV, ANCA-associated vasculitis; ANCA, antineutrophil cytoplasmic antibody; MetS, metabolic syndrome; MPA, microscopic polyangiitis; GPA, granulomatosis with polyangiitis; EGPA, eosinophilic GPA; MPO, myeloperoxidase; P, perinuclear; PR3, proteinase 3; C, cytoplasmic; BVAS, Birmingham vasculitis activity score; FFS, five-factor score; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; HDL, high-density lipoprotein; MSSS, metabolic syndrome severity score; ESKD, end-stage kidney disease; CVA, cerebrovascular accident; CVD, cardiovascular disease.